Source: Eur Respir J 2013; 42: 891-892
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gibson Peter G.. Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD. Eur Respir J 2013; 42: 891-892

Member's Comments

No comment yet.

Related content which might interest you: The need for asthma phenotyping Source: International Congress 2017 – PG15 Asthma stratification Year: 2017 The need for asthma phenotyping Source: International Congress 2018 – PG17 Asthma phenotyping Year: 2018 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Potential usefulness of phenotyping in asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 How can we improve our assessment of inflammation in clinical studies of COPD that use bronchial biopsies? Source: Eur Respir J 2006; 27: 248-249 Year: 2006 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Clinical clustering of COPD patients is useful to predict future COPD exacerbations Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 Is antibiotic treatment during asthma exacerbation necessary ? Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Is infection screening in BAL fluid useful in children with chronic obstructive airway disease unresponsive to anti-asthmatic treatment? Source: Eur Respir J 2006; 28: Suppl. 50, 310s Year: 2006 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Ykl-40 and phenotyping of severe asthma Source: International Congress 2019 – Immunopathological mechanisms of lung disease Year: 2019 Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020